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INTRODUCTION
The Bjork-Shiley Monostrut valve is tilting disc mechan-
ical valve prosthesis. The original Bjork-Shiley valve was
referred to as the Delrin Bjork valve that was developed after
the ball and horizontal disc valves. Many modifications have
followed including the pyrolite carbon leaflet, single inflow
strut, tantalum strut, and the convexo-concave valve (1, 2).
The convexo-concave valve had defects of the outflow strut
fracture; the monostrut valve was introduced to prevent
outflow strut fracture (3). We have used the Bjork-Shiley
monostrut valve for 14 yr since 1977. Here we present our
data on the long-term outcomes of our experience with this
valve.
MATERIALS AND METHODS
Between 1970 and 1990, about 170 Bjork-Shiley Monos-
trut valves were used in 139 patients at our hospital. Here we
present the long-term surgical outcomes of 101 patients whose
medical records were available for evaluation. Between Novem-
ber 1983 and February 1990, 101 patients underwent valve
replacement using the Bjork-Shiley Monostrut valve. There
were 60 male patients and 41 females with a mean age of 34.5
±10.4 (range, 10-59 yr). Among them, 72 mitral valves, 63
aortic valves (7 underwent Bentall operation), and 2 tricuspid
valves were replaced; overall, 137 Bjork-Shiley Monostrut
valves were used for valve replacement. Fifty-nine patients
underwent single valve replacement (35 mitral and 24 aor-
tic), 38 had double valve (mitral with aortic), and 4 had triple
valve replacement. Out of 42 multiple valve replacements,
6 patients had other valvular prostheses: St. Jude in 3 (1 in
aortic and 2 in tricuspid position), Ionescue-Shiley in 2, and
Hancock in 1 (mitral position). For the mitral valve replace-
ments we used a 23 mm sized valve in one patient, 27 mm
in four, 29 mm in 15, 31 mm in 38, and 33 mm in 14. For
the aortic valve replacements, we used 19 mm-sized valve
in two patients, 21 mm in 13, 23 mm in 19, 25 mm in 19,
27 mm in five, 29 mm in four, and 31 mm in two. For the
tricuspid valve replacements, we used 33 mm-sized valve in
two patients. The combined operative procedures were left
atrial auricle obliteration in 27, tricuspid annuloplasty in
17, tricuspid commissurotomy in one, mitral valvuloplasty
in one, and correction of congenital anomalies in five cases.
The valvular pathology included rheumatic fever in 65,
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Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
The Bjork-Shiley Monostrut valve is tilting disc mechanical valve prosthesis. This
study was designed to present the long-term outcome of our experience. One hun-
dred and thirty-seven Bjork-Shiley Monostrut valves were implanted in 101 consecu-
tive patients from November 1983 to February 1990. There were 60 male and 41
female with mean age of 34.5 yr at the time of operation. Fifty-nine patients under-
went single valve replacement, 38 had double valve, and 4 had triple valve replace-
ment. There were six in-hospital deaths (5.9%): three from cardiopulmonary bypass
weaning failure and one each from septic shock, sudden cardiac arrest, and uncon-
trollable bleeding. Mean duration of follow-up was 181.2± ±76.2 months. Overall
survival was 86.2% at 15 yr and 83.1% at 20 yr. Patients with mitral valve replace-
ment had 93.5% and 90.2% cumulative survival at 10 and 15 yr, respectively, while
patients with aortic valve replacement had 91.1% and 86.5% cumulative survival
at 10 and 15 yr. Two groups had no significant difference in survival. Double valve
replacement patients had 92.2% and 84.0% survival at 10 and 15 yr, respectively.
There were no significant differences in survival between the single and double
valve replacement groups. Freedom from thromboembolism was noted in: 97.8%,
97.8%, 96.4% and 87.8% at 5, 10, 15 and 20 yr, respectively. Absence of endo-
carditis was noted in 98.6% and 94.8% at 15 and 20 yr. Absence of reoperation
was 92.5% at 20 yr. In conclusion, the Bjork-Shiley Monostrut valve is reliable, with
a similar incidence of valve-related morbidity as in other mechanical valves.
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bioprosthetic valve failure in 13, endocarditis in 10 (8 native
and 2 prosthetic), degenerative disease in two, and unspeci-
fied in 11 patients. The New York Heart Association (NY-
HA) functional classification of patients was class II or I in
30 patients, class III in 61, and class IV in 10.
All patients were treated with warfarin postoperatively after
extubation; the target INR (prothrombin time, internation-
al normalized ratio) was 1.7-2.3. After discharge, the INR was
followed up every one to two months to control the warfarin
dose. In general, patients were followed up every one to two
months at the outpatient clinic. The data was analyzed based
on the guidelines for reporting morbidity and mortality after
cardiac valvular operations reported by Edmunds et al. (4).
RESULTS
Early deaths
There were six in-hospital deaths (5.9%): two after mitral
and aortic valve replacement and one each after mitral valve
replacement, aortic valve replacement, triple valve replacement,
and modified Bentall operation. The causes of mortality were
cardiopulmonary bypass weaning failure in three, septic shock
in one, sudden cardiac arrest in one, and uncontrollable bleed-
ing in one patient. Cardiopulmonary bypass weaning failure
occurred in three patients; one of them previously underwent
tissue valve replacement for endocarditis. One patient who
died of septic shock had fungal endocarditis after tissue valve
replacement and had acute renal failure postoperatively. Sud-
den cardiac arrest occurred in one patient five weeks after sur-
gery. One patient who underwent the Bentall procedure died
from sudden uncontrollable bleeding on the first day postop-
eratively; a tear around the anastomosis site was strongly sus-
pected.
Late deaths (Table 1)
There were 13 late deaths (13.7%) during the follow-up pe-
riod. The initial operations were mitral and aortic valve re-
placement in four, mitral and aortic valve replacement with
tricuspid annuloplasty in two, mitral valve replacement with
tricuspid annuloplasty in two, mitral valve replacement in two,
mitral, aortic and tricuspid valve replacement in one, aortic
valve replacement with tricuspid annuloplasty in one, and the
Bentall procedure in one patient. The causes of death were cere-
bral infarction in three, sepsis in two, congestive heart failure
in two, cerebral hemorrhage in one, sudden cardiac arrest in
one, multiorgan failure in one patient after a second operation,
cardiopulmonary weaning failure after the third operation in
one, lymphoma in one and chronic liver disease in one patient.
Late morbidity (Table 2)
There were 13 valve-related morbidities in 12 patients.
Five patients had mitral valve replacement, 3 had aortic and
mitral valve replacement, 1 had aortic valve replacement and
tricuspid annuloplasty, 1 had aortic valve replacement, 1 had
mitral/aortic/tricuspid valve replacement, and 1 had the Ben-
tall operation.
Valve failure
There was one patient with structural valve degeneration.
A 36-yr-old male underwent mitral valve replacement and 26
months later, prosthetic valve regurgitation was noted on ec-
hocardiography; the patient had no other specific symptoms.
The patient is currently on routine follow-up with periodic
echocardiographic examinations.
There were two patients with non-structural valve failure.
One patient with a bicuspid aortic valve had aortic regurgita-
tion with endocarditis. Two years after aortic valve replacement,
paravalvular leakage was noted on echocardiography; the pa-
tient had no symptoms or signs, and he is being managed con-
servatively. The other patient had a ventricular septal defect
with aortic regurgitation. Paravalvular leakage was noted right
after the valve replacement, and two years later, severe hemolyt-
ic anemia with prosthetic valve endocarditis was detected. The
patient underwent another aortic valve replacement with a St
Jude mechanical valve; however, the paravalvular leakage per-
sisted. Twenty-two months after the second operation, the third
Causes of deaths Number
Cerebral infarction 3
Sepsis 2
Congestive heart failure 2
Death after redo valve surgery 2
Sudden cardiac arrest 1
Cerebral hemorrhage  1
Lymphoma 1
Chronic liver disease 1
Table 1. Causes of late death
Complications Number
Event/100 
patient-year
Structural deterioration 1 0.065
Nonstructural dysfunction 2 0.131
Thromboembolism 8 0.590
Cerebral 6
Femoral 1
Ocular 1
Anticoagulation-related hemorrhage 6 0.393
Leg ischemia 2
Conjunctiva 1
Jejunum 1
Uterine 1
Oral 1
Prosthetic valve endocarditis 2 0.131
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operation was performed; the patient died due to periopera-
tive low cardiac output. 
Thromboembolism
Thromboembolism occurred in eight patients. Five pa-
tients had mitral valve replacement, two had double valve
replacement, one had triple valve surgery, and one had Ben-
tall operation. Six patients had cerebral infarction, one had a
femoral artery embolism, and one had an ocular artery em-
bolism. All patients who had an embolic event had atrial
fibrillation at the time of the embolism.
Anticoagulation-related hemorrhage
There were six patients who had anticoagulation-related
hemorrhage that required hospital care; some had severe cere-
bral hemorrhage. Two patients had mitral valve replacement,
two had aortic valve replacement, one had double valve replace-
ment, and one had the Bentall operation. No patient had major
bleeding after tricuspid valve replacement. The location of the
hemorrhage included the lower extremities, conjunctiva, uterus,
jejunum, and mouth (after tooth extraction).
Prosthetic valve endocarditis 
There were two cases of prosthetic valve endocarditis. One
patient had paravalvular leakage after surgery; no microor-
ganism was identified on blood culture. However, there was
purulent material noted at the prosthetic valve during
surgery for the problem. The paravalvular leakage persisted,
and the third operation was performed; the patient died due
to low cardiac output. The other patient had mitral valve
replacement; after tooth extraction a high fever and leuko-
cytosis were noted. The patient and laboratory findings im-
proved with antibiotics. There were no microorganisms de-
tected on blood cultures, and the patient was diagnosed with
endocarditis because his laboratory findings were normalized
and the fever subsided after treatment with antibiotics.
Reoperation for valve replacement
There were two reoperations for valve replacement. One
patient had paravalvular leakage and endocarditis after the first
operation and expired after the third operation as noted above.
The other patient had mitral valve replacement 14 yr later after
the initial surgery; she stopped her warfarin medication dur-
ing pregnancy. Valve thrombosis was detected on echocardio-
graphy; she underwent a redo mitral valve replacement with
an On-X bileaflet mechanical valve.
Valve-related mortality
There were two valve-related mortalities. One patient who
had double valve replacement died after a struggle with her
husband; she died suddenly. The other patient also died
suddenly after Bentall operation; we could not identify the
cause of death. 
Long-lasting sequelae
There were seven long-lasting sequelae. All had mitral valve
replacement and cerebral infarction after surgery. One patient
had a depressive disorder after surgery.
Overall survival
The mean follow-up duration was 181.2±76.2 (0.3-263.8)
months. The overall survival (except early death) was 86.2%
at 15 yr and 83.1% at 20 yr. Patients who had mitral valve
replacement had 93.5% and 90.2% cumulative survival at
10 and 15 yr, while patients who had aortic valve replacement
had 91.1% and 86.5% cumulative survival at 10 and 15 yr,
respectively (Fig. 1). The two groups had no significant differ-
ence in the rate of survival. Double valve replacement patients
had 92.2% and 84.0% survival at 10 and 15 yr, respectively.
There were no significant differences in survival rates between
the single and double valve replacement groups.
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Fig. 1. Comparison of survival among mitral valve, aortic valve,
and double valve replacement.
51 01 52 0
Year
Mitral valve only
Double valve
10 yr 15 yr
Mitral valve only:  93.6% 90.2%
Aortic valve only: 91.1% 86.5%
Double valve: 92.0% 84.0%
p=0.720
Aortic valve only
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Fig. 2. Freedom from valve-related morbidity.
51 01 52 0
Year
Freedom from thromboembolism 5 yr: 97.8%
10 yr: 97.8%
15 yr: 96.4%
20 yr: 87.8%
Freedom from reoperation 20 yr: 92.5%
Freedom from endocarditis 15 yr: 98.6%
20 yr: 94.8%Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve 1063
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Morbidity profiles
The morbidity profiles of the study patients are shown in
Fig. 2. Freedom from thromboembolism was noted in 97.8%,
97.8%, 96.4% and 87.8% at 5, 10, 15 and 20 yr, respective-
ly. Absence of endocarditis was noted in 98.6% and 94.8% at
15 and 20 yr. Absence of reoperation was 92.5% at 20 yr. We
could not get exact data about anticoagulation-related bleed-
ing, and therefore, we did not suggest our result in this series.
DISCUSSION
Most of the ball valves or horizontal disc valves are centrally
occluding valves. They have different upper and lower sys-
tolic pressure. To improve this type of device, the Wada tilt-
ing disc valve was developed; however, this valve had a fixed
hinged point. The Delrin Bjork valve was developed in 1968
with no hinged point and other improvements. It is now used
worldwide. In 1971 the Delrin plate was changed to a pyro-
lite carbon plate because the plate deformed with moisture;
to protect against fracture, an inflow strut was linked to an
eccentric valvular orifice (5). In 1975, to be able to detect valvu-
lar obstruction by thromboembolism easily, the valvular ori-
fice was changed to tantalum, which is radioopaque (6). In
1979, in order to reduce the risk of thromboembolism, the
flat plate was reshaped to be concave, and the angular aper-
ture was reformed 60 degrees. In order to decrease the pres-
sure gradient, the angular aperture was changed to 70 degrees;
however, as a result, outflow strut fracture occurred; then the
manufacturing production of the valve was suspended. Lind-
blom et al. (3) reported 1,461 cases of Bjork-Shiley valve re-
placements; the five-year valve failure rate with a 60 or 70-
degree angular aperture was 0.6% and 2.8%, respectively. Or-
szulak et al. (7) used Delrin valve, 60 degree opening angled
valve and convexo-concaved valve. They reported the preva-
lence of patients remaining free of event at 5 and 10 yr at 61
% and 42%, respectively.
The Monostrut Bjork-Shiley valve was developed to pro-
tect from outflow strut fracture. In addition, to reduce the
risk of thromboembolism a concave plate with an angular
aperture of 70 degrees was developed. Nakano et al. (8) re-
ported that there were no cases with structural valve deteri-
oration when the Monostrut Bjork-Shiley valve was used.
The freedom from valve-related morbidity and mortality
was 86±2.0% at 5 yr: 86±9.5% for aortic, 87±3.3% for
mitral, and 75±7.3% for double valve replacement. Effec-
tive valve areas (average) of 12 mitral and 12 aortic valve
prostheses were calculated at rest and during bicycle exer-
cise: 2.4 cm2 at rest and 2.8 cm2 during exercise in 27 mm
aortic valves, 2.4 cm2 at rest and 3.0 cm2 during exercise in
25 mm aortic valves, 2.0 cm2at rest and 2.4 cm2during exer-
cise in 27 mm mitral valves, and 2.6 cm2 at rest and 2.5 cm2
during exercise in 29 mm mitral valve. Therefore, the Bjork-
Shiley Monostrut valve was accepted as reliable with a low
incidence of valve-related morbidity and with satisfactory
hemodynamic characteristics at rest and during exercise. Lind-
blom et al. (9) reported that the three-year survival (early
mortality excluded) was 88.6% (aortic valve replacement
89.2%, mitral valve replacement 89.3%, and double valve
replacement 82.5%). The three-year rate of freedom from
thromboembolism in patients receiving anticoagulants was
as follows: aortic valve replacement 97.5%, mitral valve re-
placement 92.8%, and double valve replacement 100%. There
were no cases of valve thrombosis or fatal embolism. By con-
trast, there were two cases of aortic valve thrombosis among
34 patients with aortic valve replacement who did not receive
anticoagulation. 
Thromboembolism is one of the most serious complications
of mechanical valve replacement procedures. The incidence
of thromboembolism was 0.6%/patient-year in our series,
slightly lower than that reported by Nakano (8), 1.5%/patient-
year, and that by Nashef et al. (10), 2%/patient-year. For pa-
tients with mitral valve replacement, the incidence was 0.3%/
patient-year; there was no embolism observed in patients with
aortic valve replacement; patients with double valve replace-
ment had an incidence of 0.4%/patient-year, and for patients
with triple valve replacement it was 1.3%/patient-year. How-
ever, there were only five patients with triple valve replace-
ments. In these patients we used multiple different valves for
replacement; therefore, it is difficult to determine a meaning-
ful incidence rate in this group of patients. The three-year sur-
vival without thromboembolism in the aortic and mitral valve
replacement patients was 100%, and these findings are con-
sistent with those of Crawford (1) who reported rates of 98%
and 93%, respectively in 1987 Daenen et al. (11) reported
their mid-term result of the Bjork-Shiley Monostrut valve in a
large series. For 647 patients, actuarial freedom from throm-
boembolism was 86% at 6 yr; there were no cases of valve th-
rombosis, and patients having thromboembolic event showed
a higher probability of late death after native valve replacement.
Anticoagulation-related complications occurred in 0.4%/
patient-year, lower than the rate reported by Bjork et al. (1)
(2.2%/patient-year). We had no anticoagulation related dea-
th; however, there was 0.5%/patient-year mortality. In addi-
tion, the St Jude valve and Carbomedics had a 1.43%/patient-
year and 2.64%/patient-year anticoagulation-related compli-
cation rate, which was almost the same as the Bjork-Shiley
valve rates. We used the same strategy for anticoagulation ther-
apy in all patients who had mechanical valve replacement.
From the results of our long-term evaluation of the Bjork-
Shiley valve, it appears to have similar anticoagulation-related
hemorrhage risks but slightly higher thromboembolism risks
than in other mechanical valves. We are now using a bileaflet
mechanical valve instead of tilting disc prosthesis; however,
the Bjork-Shiley Monostrut valve had good long-term results
without significant complications and a mortality rate com-
parable to those in other valves, which is in line with other
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reports (12, 13). From these observations, we state that the
performance of the Monostrut Bjork-Shiley valve on long-term
follow-up is acceptable and comparable with results published
by other centers using the same type of prosthesis (12-15).
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